Cargando…

New Points of Departure for More Global Influenza Vaccine Use

Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the dru...

Descripción completa

Detalles Bibliográficos
Autor principal: Kiseleva, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563509/
https://www.ncbi.nlm.nih.gov/pubmed/32718042
http://dx.doi.org/10.3390/vaccines8030410
_version_ 1783595505527291904
author Kiseleva, Irina
author_facet Kiseleva, Irina
author_sort Kiseleva, Irina
collection PubMed
description Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.
format Online
Article
Text
id pubmed-7563509
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75635092020-10-27 New Points of Departure for More Global Influenza Vaccine Use Kiseleva, Irina Vaccines (Basel) Editorial Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic. MDPI 2020-07-23 /pmc/articles/PMC7563509/ /pubmed/32718042 http://dx.doi.org/10.3390/vaccines8030410 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Kiseleva, Irina
New Points of Departure for More Global Influenza Vaccine Use
title New Points of Departure for More Global Influenza Vaccine Use
title_full New Points of Departure for More Global Influenza Vaccine Use
title_fullStr New Points of Departure for More Global Influenza Vaccine Use
title_full_unstemmed New Points of Departure for More Global Influenza Vaccine Use
title_short New Points of Departure for More Global Influenza Vaccine Use
title_sort new points of departure for more global influenza vaccine use
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563509/
https://www.ncbi.nlm.nih.gov/pubmed/32718042
http://dx.doi.org/10.3390/vaccines8030410
work_keys_str_mv AT kiselevairina newpointsofdepartureformoreglobalinfluenzavaccineuse